CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer

Cancer Science

Volumn 106, Issue 10, 2015, Pages 1421-1428

  Tjhay, Francisca ^a   Motohara, Takeshi ^a   Tayama, Shingo ^a   Narantuya, Dashdemberel ^a   Fujimoto, Koichi ^a   Guo, Jianying ^a   Sakaguchi, Isao ^a   Honda, Ritsuo ^a   Tashiro, Hironori ^a   Katabuchi, Hidetaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cancer stem cell; CD44; Ovarian cancer; Peritoneal metastasis; Prognosis

Indexed keywords

CARBOPLATIN; CD44V6 ANTIGEN; CISPLATIN; FIBRONECTIN; NERVE CELL ADHESION MOLECULE; PACLITAXEL; UVOMORULIN; VIMENTIN; CADHERIN; HERMES ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOREDUCTIVE SURGERY; ES 2 CELL LINE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL ADHESION; CELL PROLIFERATION; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; NUDE MOUSE; OVARY; OVARY TUMOR; PATHOLOGY; PERITONEUM; PERITONEUM TUMOR; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; BIOMARKERS, TUMOR; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; OVARY; PERITONEAL NEOPLASMS; PERITONEUM; TREATMENT OUTCOME; VIMENTIN;

EID: 84945156824     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12765     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-81.
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-64.
4. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-28.
5. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-5.
6. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-67.
7. Tanabe KK, Nishi T, Saya H. Novel variants of CD44 arising from alternative splicing: changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog 1993; 7: 212-20.
8. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-74.
9. Tanabe KK, Saya H. The CD44 adhesion molecule and metastasis. Crit Rev Oncog 1994; 5: 201-12.
10. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1855-66.
11. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
12. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 1995; 72: 1494-7.
13. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443-55.
14. Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers 2011; 26: 50-7.
15. Kamura T, Sakai K, Kaku T, Kobayashi H, Mitsumoto M, Tsuneyoshi M, et al. Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: an immunohistochemical analysis. Oncol Rep 1999; 6: 97-101.
16. Gardner MJ, Catterall JB, Jones LM, Turner GA. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin Exp Metastasis 1996; 14: 325-34.
17. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
18. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
19. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-28.
20. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65.
21. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-20.
22. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
23. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012; 3: 883.
24. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014; 14: 342-56.
25. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011; 6: e24217.
26. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6 + subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008; 26: 725-33.
27. Motohara T, Masuko S, Ishimoto T, Yae T, Onishi N, Muraguchi T, et al. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 2011; 32: 1597-606.
28. Tavassoli FA, Devilee P; World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
29. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83: 135-66.
30. Motohara T, Tashiro H, Miyahara Y, Sakaguchi I, Ohtake H, Katabuchi H. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. Cancer Sci 2010; 101: 1550-6.
31. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-8.
32. Unternaehrer JJ, Zhao R, Kim K, Cesana M, Powers JT, Ratanasirintrawoot S, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
33. Hong SC, Song JY, Lee JK, Lee NW, Kim SH, Yeom BW, et al. Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res 2006; 32: 379-86.
34. Sakai K, Kaku T, Kamura T, Kinukawa N, Amada S, Shigematsu T, et al. Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. Gynecol Oncol 1999; 72: 360-6.
35. Shi J, Zhou Z, Di W, Li N. Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 2013; 13: 182.
36. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011; 71: 634-9.
37. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
38. Mitsui H, Shibata K, Suzuki S, Umezu T, Mizuno M, Kajiyama H, et al. Functional interaction between peritoneal mesothelial cells and stem cells of ovarian yolk sac tumor (SC-OYST) in peritoneal dissemination. Gynecol Oncol 2012; 124: 303-10.